OrthoSpace develops InSpace™, an orthopedic biodegradable balloon system used as a minimally invasive treatment for rotator cuff injuries. The device is marketed in Europe, Israel, Russia and Hong Kong, where about 10,000 balloons have been implanted. The procedure can be performed in an outpatient setting and is intended to reduce shoulder pain and improve range of motion. The company is led by CEO Itay Barnea. OrthoSpace is pursuing a US Investigational Device Exemption (IDE) FDA study and plans to expand commercial activities in Europe, South America and Asia. The recent financing is intended to support the IDE study, international commercial build-out and working capital. OrthoSpace provides InSpace, an orthopedic biodegradable balloon system designed to treat severe rotator cuff tears. The device is CE Marked and is commercialized in Europe and Israel. The company has been granted an Investigational Device Exemption (IDE) to initiate a pivotal human clinical study in the United States. Leadership includes CEO Itay Barnea and Co‑Founder and Medical Director Assaf Dekel MD. OrthoSpace recently completed a financing of undisclosed amount to support continued market adoption, its clinical study programs and entry into emerging markets. The company is based in Caesarea, Israel.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2016